How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics, Inc. (NASDAQ:JNCE) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.15. During the same quarter in the prior year, the company earned ($0.73) earnings per share.

What is Richard Murray Ph.D's approval rating as Jounce Therapeutics' CEO?

45 employees have rated Jounce Therapeutics Chief Executive Officer Richard Murray Ph.D on Glassdoor.com . Richard Murray Ph.D has an approval rating of 97% among the company's employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jounce Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Exelixis (EXEL) , Teva Pharmaceutical Industries (TEVA) , Bausch Health Companies (BHC) , CRISPR Therapeutics (CRSP) , Novavax (NVAX) , Mylan (MYL) , Progenics Pharmaceuticals (PGNX) , Adaptimmune Therapeutics (ADAP) , Incyte (INCY) and Nektar Therapeutics (NKTR) .

When did Jounce Therapeutics IPO?

Jounce Therapeutics (JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

NASDAQ:JNCE

Jounce Therapeutics (JNCE) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free JNCE Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $1.88
▼
$1.93
50-Day Range: $1.84
▼
$1.94
52-Week Range: $0.58
▼
$5.87

Volume: 11.60 million shs
Average Volume: 2.46 million shs
Market Capitalization: $98.94 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Jounce Therapeutics alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Jounce Therapeutics Stock (NASDAQ:JNCE)

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Ad Crypto 101 Media

SHOCKING Crypto Leak…

Claim your free seat by clicking here now.

JNCE Stock News Headlines

November 27, 2023 | bizjournals.com

San Diego VC, OrbiMed make competing buyout offers for struggling Theseus

September 19, 2023 | tmcnet.com

Jounce Media Designates Yahoo Backstage as the Open Web's Largest MFA-Free Supply Source

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

September 18, 2023 | finance.yahoo.com

Kargo Is Industry’s Only Scaled 100% Premium SSP According To Jounce Media

September 5, 2023 | tmcnet.com

Mediavine Represents the Largest Percentage of DEI-owned Websites, Per Data from Jounce Media

May 5, 2023 | benzinga.com

Board Member at Jounce Therapeutics Exercises Options Worth $324K

May 4, 2023 | benzinga.com

Board Member at Jounce Therapeutics Exercises Options Worth $172K

May 4, 2023 | benzinga.com

Jounce Therapeutics Director Acquires 51,400 Shares After Exercising Company Stock Options

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

May 4, 2023 | benzinga.com

Jounce Therapeutics Board Member Acquires 1,883,269 Shares After Exercising Company Stock Options

May 3, 2023 | finance.yahoo.com

Jounce Therapeutics Announces Closing of Tender Offer

April 29, 2023 | seekingalpha.com

JNCE Jounce Therapeutics, Inc.

April 17, 2023 | finance.yahoo.com

The past five years for Jounce Therapeutics (NASDAQ:JNCE) investors has not been profitable

March 29, 2023 | benzinga.com

What is Wall Street's Target Price for Jounce Therapeutics Inc (JNCE) Stock Monday?

March 27, 2023 | msn.com

Buyout Offer Sends Jounce Jumping 20%

March 27, 2023 | marketwatch.com

Jounce Therapeutics Shares Rally on Buyout Deal >JNCE

March 27, 2023 | marketwatch.com

Jounce Therapeutics Agrees to Buyout, Drops Redx Deal >JNCE

March 27, 2023 | finance.yahoo.com

Jounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobs

March 23, 2023 | benzinga.com

Moore Kuehn Encourages JNCE, USX, INDT, and BHWB Investors to Contact Law Firm

March 17, 2023 | 247wallst.com

Tang Capital Partners Now Owns 10.2% of Jounce Therapeutics

March 16, 2023 | finance.yahoo.com

Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer

March 16, 2023 | finance.yahoo.com

Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences

March 15, 2023 | benzinga.com

10% Owner of Jounce Therapeutics Makes $85K Buy

March 15, 2023 | finance.yahoo.com

Why Jounce Therapeutics Stock Is Moving Higher Today?

March 15, 2023 | markets.businessinsider.com

Concentra Biosciences Proposes To Acquire Jounce Therapeutics - Quick Facts

March 15, 2023 | msn.com

Tang Capital Partners Now Owns 10.20% of Jounce Therapeutics (JNCE)

March 15, 2023 | marketwatch.com

Jounce Therapeutics Jumps Premarket on Buyout Bid >JNCE

See More Headlines

Receive JNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:JNCE
CUSIP: N/A
CIK: 1640455
Web: www.jouncetx.com
Phone: (857) 259-3840
Fax: N/A
Employees: 137
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-50,920,000.00
Net Margins: N/A
Pretax Margin: -61.93%
Return on Equity: -30.90%
Return on Assets: -26.31%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.37
Quick Ratio: 8.37

Sales & Book Value

Annual Sales: $82 million
Price / Sales: 1.21
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.54 per share
Price / Book: 0.53

Miscellaneous

Outstanding Shares: 52,630,000
Free Float: 48,993,000
Market Cap: $98.94 million
Optionable: Optionable
Beta: 0.75

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Kimberlee Cobleigh Drapkin
President, Chief Financial Officer & Treasurer
Eric Laub
Head-Investor & Media Relations
Ted Harding
Senior Vice President-Human Resources
Jacquelyn Fahey Sandell
Secretary & Chief Legal Officer
Allison Nance
VP-Regulatory Affairs & Quality Assurance

Key Competitors

View All Competitors

JNCE Stock Analysis - Frequently Asked Questions

How were Jounce Therapeutics' earnings last quarter?: Jounce Therapeutics, Inc. (NASDAQ:JNCE) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.15. During the same quarter in the prior year, the company earned ($0.73) earnings per share.
What is Richard Murray Ph.D's approval rating as Jounce Therapeutics' CEO?: 45 employees have rated Jounce Therapeutics Chief Executive Officer Richard Murray Ph.D on Glassdoor.com. Richard Murray Ph.D has an approval rating of 97% among the company's employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Jounce Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), CRISPR Therapeutics (CRSP), Novavax (NVAX), Mylan (MYL), Progenics Pharmaceuticals (PGNX), Adaptimmune Therapeutics (ADAP), Incyte (INCY) and Nektar Therapeutics (NKTR).
When did Jounce Therapeutics IPO?: Jounce Therapeutics (JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

This page (NASDAQ:JNCE) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Jounce Therapeutics (JNCE) Stock Price, News & Analysis

About Jounce Therapeutics Stock (NASDAQ:JNCE)

JNCE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

JNCE Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info